190 related articles for article (PubMed ID: 22234876)
1. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.
Levitsky J; Mathew JM; Abecassis M; Tambur A; Leventhal J; Chandrasekaran D; Herrera N; Al-Saden P; Gallon L; Abdul-Nabi A; Yang GY; Kurian SM; Salomon DR; Miller J
Hepatology; 2013 Jan; 57(1):239-48. PubMed ID: 22234876
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
3. Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents.
Levitsky J; Miller J; Wang E; Rosen A; Flaa C; Abecassis M; Mathew J; Tambur A
Hum Immunol; 2009 Mar; 70(3):146-50. PubMed ID: 19141306
[TBL] [Abstract][Full Text] [Related]
4. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
Fourtounas C; Dousdampanis P; Sakellaraki P; Rodi M; Georgakopoulos T; Vlachojannis JG; Mouzaki A
Am J Nephrol; 2010; 32(1):1-9. PubMed ID: 20484893
[TBL] [Abstract][Full Text] [Related]
5. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
6. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.
Kim KW; Chung BH; Kim BM; Cho ML; Yang CW
Immunology; 2015 Jan; 144(1):68-78. PubMed ID: 24974886
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients.
Chu ZQ; Ji Q
Transplant Proc; 2013; 45(1):153-6. PubMed ID: 23375290
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus.
Levitsky J; Burrell BE; Kanaparthi S; Turka LA; Kurian S; Sanchez-Fueyo A; Lozano JJ; Demetris A; Lesniak A; Kirk AD; Stempora L; Yang GY; Mathew JM
Hepatology; 2020 Aug; 72(2):569-583. PubMed ID: 31721246
[TBL] [Abstract][Full Text] [Related]
9. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of Tregs and Th17/Th1 cells by a sirolimus-based regimen might be dependent on STAT-signaling in renal transplant recipients.
Li Y; Shi Y; Liao Y; Yan L; Zhang Q; Wang L
Int Immunopharmacol; 2015 Sep; 28(1):435-43. PubMed ID: 26186486
[TBL] [Abstract][Full Text] [Related]
11. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
12. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
Ghazal K; Stenard F; Dahlqvist G; Barjon C; Aoudjehane L; Scatton O; Conti F
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
[TBL] [Abstract][Full Text] [Related]
13. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
14. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction.
Levitsky J; Gallon L; Miller J; Tambur AR; Leventhal J; Flaa C; Huang X; Sarraj B; Wang E; Mathew JM
Transplantation; 2011 Jan; 91(2):199-206. PubMed ID: 21239962
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
[TBL] [Abstract][Full Text] [Related]
16. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
17. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells.
Gallon L; Traitanon O; Yu Y; Shi B; Leventhal JR; Miller J; Mas V; L X; Mathew JM
Transplantation; 2015 Sep; 99(9):1774-84. PubMed ID: 25905982
[TBL] [Abstract][Full Text] [Related]
18. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
19. Indications and efficacy of conversion from tacrolimus- to sirolimus-based immunosuppression in pediatric patients who underwent liver transplantation for unresectable hepatoblastoma.
Hendrickson RJ; Sujka J; Fischer R; Manalang M; Daniel J; Andrews WS
Pediatr Transplant; 2019 May; 23(3):e13369. PubMed ID: 30719825
[TBL] [Abstract][Full Text] [Related]
20. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.
McAlister VC; Peltekian KM; Malatjalian DA; Colohan S; MacDonald S; Bitter-Suermann H; MacDonald AS
Liver Transpl; 2001 Aug; 7(8):701-8. PubMed ID: 11510015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
